

PATENT ASSIGNMENT

Electronic Version v1.1
 Stylesheet Version v1.1

SUBMISSION TYPE:	NEW ASSIGNMENT
NATURE OF CONVEYANCE:	RELEASE BY SECURED PARTY
CONVEYING PARTY DATA	
Name	Execution Date
TIGER TECHNOLOGY LIMITED	08/01/2007
RECEIVING PARTY DATA	
Name:	CELL WORKS DIAGNOSTICS INC.
Street Address:	6200 SEAFORTH STREET, FREEPORT CENTRE
Internal Address:	HOLABIRD BUSINESS PARK
City:	BALTIMORE
State/Country:	MARYLAND
Postal Code:	21224
PROPERTY NUMBERS Total: 3	
Property Type	Number
Application Number:	09430175
Application Number:	09501179
Application Number:	09930175
CORRESPONDENCE DATA	
Fax Number:	(650)493-6811
<i>Correspondence will be sent via US Mail when the fax attempt is unsuccessful.</i>	
Phone:	650 496 7543
Email:	nbouch@wsgr.com
Correspondent Name:	WSGR c/o Nancy Bouch, Sr Paralegal
Address Line 1:	650 PAGE MILL ROAD
Address Line 2:	FH 2-1 / P10
Address Line 4:	PALO ALTO, CALIFORNIA 94304
ATTORNEY DOCKET NUMBER:	32055.006
NAME OF SUBMITTER:	Nancy Bouch

CH \$120.00 09430175

Total Attachments: 12

source=Cell Works Diagnostics - Termination in patents#page1.tif
source=Cell Works Diagnostics - Termination in patents#page2.tif
source=Cell Works Diagnostics - Termination in patents#page3.tif
source=Cell Works Diagnostics - Termination in patents#page4.tif
source=Cell Works Diagnostics - Termination in patents#page5.tif
source=Cell Works Diagnostics - Termination in patents#page6.tif
source=Cell Works Diagnostics - Termination in patents#page7.tif
source=Cell Works Diagnostics - Termination in patents#page8.tif
source=Cell Works Diagnostics - Termination in patents#page9.tif
source=Cell Works Diagnostics - Termination in patents#page10.tif
source=Cell Works Diagnostics - Termination in patents#page11.tif
source=Cell Works Diagnostics - Termination in patents#page12.tif

**TERMINATION AND RELEASE OF
SECURITY INTEREST IN PATENTS**

This Termination and Release of Security Interest in Patents (the "Termination and Release"), dated as of August 1st, 2007, is executed by TIGER TECHNOLOGY LIMITED, of 39/F West Tower, Shun Tak Centre, 200 Connaught Road, Central, Hong Kong ("Secured Party"), in favor of CELL WORKS DIAGNOSTICS INC., a Delaware corporation (together with its successors and assigns, "Grantor"). All capitalized terms defined in the Security Agreement (defined below) are used with the same meanings, unless otherwise defined, in this Termination and Release.

RECITALS

A. WHEREAS, Grantor and Secured Party entered into a Security Agreement, dated as of October 14, 2003 (the "Security Agreement"), which provides for the extensions of credit to be made to Grantor by Secured Party;

B. WHEREAS, pursuant to the terms of the Security Agreement, Grantor granted Secured Party a security interest in all of Grantor's right, title and interest in, to and under all trademarks, trademark licenses, trade names, service marks, logos, patents set out on Schedules 1 and Schedule A hereto (to the extent applicable to Grantor), and the related goodwill, whether now or hereafter existing and whether now owned or hereafter acquired (the "Collateral"), to secure Grantor's obligations to the Secured Party under the Security Agreement;

C. WHEREAS, the Security Agreement was filed with the United States Patent and Trademark Office on November 12, 2003, at Reel/Frame 014670/0326, and a Corrective Assignment filed on August 12, 2004, at Reel/Frame 014980/0175 to evidence the security interest granted under the Agreement, including but not limited to those patents and patent applications listed on Schedule A hereto;

D. WHEREAS, Grantor and Secured Party have agreed to liquidate the Collateral by auction through IP Auctions, Inc. and to apply the auction sale proceeds on account of Grantor's obligations to Secured Party;

E. WHEREAS, the winning bidder for the Collateral has requested Secured Party to execute this Termination and Release.

NOW, THEREFORE, for good and valuable consideration, the receipt and sufficiency of which is hereby acknowledged, Secured Party hereby expressly terminates and releases its security interest in each patent and patent application listed or referred to on Schedules 1 and Schedule A hereto; furthermore, Secured Party hereby expressly confirms the quitclaim of all right, title and interest in and to each patent and patent application listed or referred to on Schedules 1 and Schedule A hereto.

[Signature page follows]

IN WITNESS WHEREOF, Secured Party has executed and delivered this Termination and Release as of the day and year first above written.

TIGER TECHNOLOGY LIMITED

By:  _____

Name: Ho Chiu King, Pansy _____

Title: Director _____

SCHEDULE 1: LIST OF IP

Patents

1. All patents and patent applications as attached and marked in Schedule (A).
2. All rights to apply for patent protection worldwide based on the patents and patent applications specified at 1 above and/or based on improvements, findings or discoveries flowing from or otherwise howsoever deriving from the invention, technology, know-how or within the disclosure in such patents and patent applications.
3. Any and all other patents and patent applications that now or in the future are or become subject to a Deed of Charge dated 15 July 2003 between Cell Works Inc. c/o Corporation Services Company, 2711 Centerville Road, Suite 400, Wilmington, Delaware 19808, USA and Tiger Technology Limited, and which are based on patents and patent applications specified at 1 and 2 above.

Licenses

1. The exclusive patent license effective 25 November 1996 granted to Cell Works Inc. ("CWI") by John Hopkins University ("the JHU License") in respect to an invention entitled "A Method of Enriching Non-Blood Cells" the subject of US Patent No.5,962,237, the benefit of which was assigned to the Grantor by CWI by an assignment dated 22 August 2003.
2. The sub-license granted under the Agreement dated 21 November 2001 by CWI to Cell Works Asia Limited in respect to the JHU License, the benefit of which was assigned to the Grantor by CWI by an assignment dated 22 August 2003.

SCHEDULE 1: PATENT DATA

BOX NO. 1

Folder	Correspondence regarding Patent Application No. 6,960,449 B2 and Patent Application No. 09/501,179
Folder	Correspondence regarding Patent Application No. 60/666,202
2 Folders	Correspondence regarding Patent Application No. 08/755,062
Folder	Correspondence regarding Patent Application No. 11/182,897
2 Folders	Correspondence regarding Australian Patent Application No. 14552/00 (Now Patent No. 772603)
Folder	Correspondence regarding Hong Kong Patent Application No. 02103067.0 (Now Patent No. HK 1042338)
Folder	Correspondence regarding United Kingdom Patent Application No. 0111742.3 (Now Patent No. 6B2361996)
2 Folders	Correspondence regarding US Patent Application No. 09/501,179
Folder	Correspondence regarding US Patent Application No. 08/832,468
2 Folders	Correspondence regarding Taiwan Patent No. 203661; Application No. 86104288
2 Folders	Correspondence regarding Chinese Patent Application No. 97195305.8
Folder	Correspondence regarding Patent Application No. 5,962,237
4 Folders	Correspondence regarding Patent Application No. 10/787,585 (2 regarding Patent Cooperation Treaty)
Loose Papers	European Patent Application No. 04715624.5 Hong Kong Patent Application No. 06106712.8 US Patent Application No. 09/150,179

BOX NO. 2

Notebook	Titled: Faulding Pharmaceuticals Notebook (potential purchaser); non-clinical toxicity-ps 185FU regarding lab results
Notebook (Unlabeled)	Journal articles/press releases; information regarding Patent No. 5,885,968; lab results
Notebook (Mislabelled)	Therapeutic Competitors; journal articles regarding cancer research, research treatments and drugs; report on LIV-1 stability
Notebook	Titled: Toxicity-Neoglycoconjugate Patient reports from year 2000 from Antech Diagnostics
Steno Pad	Notes from 1999 meetings regarding business plans
Notebook	Titled: Fed 1092 Discussions and conclusions regarding testing on mice; technology transfer to Cell Works Asia memo; journal articles; test results on LIV-1 for 2001
Notebook (Unlabeled)	Memo regarding proposed phase/clinical trial dosing scheme dated 2/20/02; lab results (some dated 2002); internet/journal articles
Notebook (Unlabeled)	Correspondence with CATO Research regarding FDA new drug application; estimations of test articles needs for LIV-1 toxicology program
Notebook (Mislabelled)	CWT Projected Operating and Development Expenses dated 10/2/03; split-off plan and agreement dated 8/22/03 among CWI, CWD & CWT; memo regarding projected burn rate and expenses dated 6/30/04
Notebook (Unlabeled)	Lab results on lab forms
Loose Folders and Papers	Research articles regarding liver, spleen, colon, and pancreas; index of research journal articles from 1964 through 1996

BOX NO. 3

Redwell	Correspondence regarding Novel testing phase/single project assurance
Hanging Folder	Correspondence regarding Phase 1 Grant Application/Budgets/Reports regarding Ligand-Directed Delivery of Anti-Cancer Drugs
Hanging Folder	Survey regarding Grant Recipients; letter dated 7/6/99 from Johns Hopkins regarding tumor markers
Redwell	SBIR Phase I proposal regarding software development for automatic scanning and analysis of fluorescent labeled prostate cancer cells
Hanging Folder	SBIR Phase II proposal regarding software development for automatic scanning and analysis of fluorescent labeled prostate cancer cells
Hanging Folder	SBIR regarding isolation and profiling of circulating PC cells in blood
2 Folders	Correspondence regarding circulating PC cells in blood; budget justification and expenditure transfers
Folder	Correspondence regarding NIH isolation and profiling reports; financial status
Folder	Correspondence regarding assistance agreement from US Army Medical Research Acquisition regarding breast cancer cells
Folder	Correspondence regarding approval of prostate cancer cell research
Folder	Single project assurance regarding NIH
Folder	Correspondence on grant regarding pancreatic cancer bloodbiopsy prognosis and prediction
Folder	Correspondence on grant regarding diagnostic liver cancer cell bloodbiopsy for treatment
Folder	Correspondence regarding Ligand-Directed Delivery of Anti-Cancer Agents
Loose Papers	Correspondence regarding a novel test for circulating prostate cancer cells
Folder	Correspondence regarding grant application Ligand Directed Delivery of Anti-Cancer Drug

Folder	NCI – Matagen final report
2 Folders	Summary Statement Grant Application - correspondence of Ligand-Directed Delivery of Anti-Cancer Drugs, including protocol for toxicity bioefficacy of LIV-1
Folder	Correspondence regarding Ligands to enhance cellular uptake of biomolecules
Folder	Correspondence regarding grant application regarding Ligand-Directed Uptake of Non-ionic Anticoders
Folder	Report regarding tissue distribution and metabolism

BOX NO. 4

Notebook (Burgundy)	Preclinical protocols regarding anti-cancer drug
5 Floppy Disks	Regarding LIV-1
4 Floppy Disks	Regarding personal chromatography software
Folder & Binder	Research regarding potential companies to perform LIV-1 testing
Loose Papers	Test results from May, June and July 2003
Spiral Notebook and Copy	Calvert Laboratories, Inc. report regarding LIV-1: An Acute Pilot Range – Finding Toxicity Study in Rats
Folder and CD Rom	Ricerca study regarding LIV-1 in 2002
3 Spiral Notebooks and 1 clipped set	Research report: CTBR study regarding LIV-1 dated 8/2003
Folder	Lab results regarding LIV-1 dated 2002 and 2003
Loose Papers and Manila Folders	<ul style="list-style-type: none"> • Journal and internet articles regarding cancer research • Lab Results • Antech Diagnostics invoices and lab forms and results

	<ul style="list-style-type: none"> • Calvert Laboratories lab results regarding LIV-1 • Ricerca report of lab results regarding LIV-1 • Cell Works LIV-1 lab results • Emerald Pharmaceuticals report regarding LIV-1
--	---

BOX 5

Notebook	Faulding Pharmaceuticals regarding progress of development of LIV-1
Spiral Notebook	CTBR report dated 6/19/03 regarding LIV-1
Folder	Correspondence regarding International Patent Application No. 2006/000552
Notebook	LIV-1 package for National Cancer Institute
3 Notebooks with Floppy Disks	Journal articles regarding detection of circulating prostate cancer cells
Manila Folders	<ul style="list-style-type: none"> • LIV-1 mouse diagrams • Research regarding LIV-1 • Documents regarding Patent No. 5,994,517 • Documents regarding Patent No. 5,962,237

BOX 6
CORPORATE DOCUMENTS

Hanging Folder	Information sent to shareholders, including stockholder resolutions via informal actions
Folder	Certificate of incorporation and amendments; board resolutions; information regarding preferred stock
Folder	Correspondence regarding Restructuring
Loose Papers	<ul style="list-style-type: none"> • Stock options • Technology Agreements • Recapitalization • Loan facility • UCC Security Agreements

	<ul style="list-style-type: none"> • Escrow Agreements • Assignments • Board and Shareholder Resolutions • Deeds • Trademark Information
Accordion File	Proprietary Right Assignments/Non-competition Agreements
Accordion File	Confidentiality Agreements
3 Redwells	Confidentiality Agreements and Assignment Agreements

BOX 7

Folders	<ul style="list-style-type: none"> • Synthesis of Ligand-directed anti-cancer drug • Lists of Cell Work's grants • Ricerca study regarding LIV-1 (1 folder, 1 plastic pouch) • Synthesis and structural analysis of LIV-1 (4 are 2002) • Grant application regarding clinical studies of circulating epithelial • Grant application regarding cancer cell biomarkers as an indicator to drug response • Correspondence regarding LIV-1 development scheduling, including IND application • Rhodia ChiRex proposal to supply LIV-1 to Cell Works • UPM Pharmaceuticals and Ricerca proposals for LIV-1 analytical support • University of Maryland proposals for LIV-1 analytical support • Journal articles regarding kidney Ligand • Information regarding Patent Application No. 6,066,625 • CTBR test/control articles and inventory receipt forms • Report regarding synthesis of LIV-1 • Science news bulletins • Correspondence regarding Patent Application No. 08/755,062 • Correspondence regarding grant application regarding Ligand-Directed Delivery of Anti-Cancer Drugs • Research regarding grant application process • Correspondence regarding grant application regarding Ligand-Directed Delivery of Anti-Cancer Drugs • Correspondence regarding Calvert Laboratories study regarding LIV-1 • Copies of checks to CTBR and supporting documentation • Correspondence regarding grant application regarding Ligand-
---------	---

	Directed Delivery of Anti-Cancer Drug
Loose Papers	<ul style="list-style-type: none"> • Correspondence regarding Patent Application No. 60/007,480 • Correspondence regarding Patent Application No. 09/282,455 • LIV-1 summary • Correspondence regarding grant application regarding Ligand's for renal targeting of chemotherapeutics • Correspondence regarding FDA responses regarding LIV-1 pre-IND meeting • Copies of checks to CATO Research and supporting documentation

BOX NO. 8

Folders	Correspondence regarding numerous patent applications
---------	---

LOOSE FOLDERS, BINDERS AND REDWELLS

Folder	Correspondence regarding Patent Application No. 09/430,175
Notebook with Folder	Correspondence regarding Patent Application No. 5,994,517; general patent information
Folder	Correspondence regarding Patent Application No. 09/430,175

SCHEDULE A
TO TERMINATION AND RELEASE
OF SECURITY INTEREST IN PATENTS

Title: Multiple Marker Characterization of Single Cell					
Reference	Application No.	Filing Date	Publication No.	Country	Status
CDW-304US CON1	11/182,897	7/18/2005	2005- 0250155	US	Docketed for Examination
CWD-304HK	HK2002010 3067	4/24/2002	HK1042338	HK	Pending. Next Annuity due 10/29/2008.
CWD-304CA	CA1999235 0692	10/29/1999	CA2350692	CA	Abandoned, but can be reinstated by paying \$1200 annuity before 10/29/2007.
Title: Class Characterization of Circulating Cancer Cells					
CWD-307	09/501,179	11/1/2005	2002- 0098535	US	Issued as U.S. Patent No. 6,960,449. First Maintenance Fee due 11/3/2008, surcharge window opens 5/1/2009, expires 11/2/2009 if no payment made.

Title: Standardized Evaluation of Therapeutic Efficacy Based on Cellular Biomarkers

CWD-404 US	10/787,585	2/27/2004	2004-0171091	US	Office Action mailed 2/21/2007. Response due 5/21/2007, extendable up to three months with payment of extension fees.
CWD-404EPO	4715624.5	2/27/2004	1604184	EPO (Check filing for designated countries)	No action currently pending.
CWD-404HK	6106712.8	2/27/2004	1086882A	HK	No action currently pending.